(Q35203790)

7 August 2017

1 reference

title

Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder (English)

1 reference

7 August 2017

main subject

irritable bowel syndrome

1 reference

1 reference

Francis A Farraye

3

1 reference

ORCID Public Data File 2021

author name string

Anthony Lembo

series ordinal

1

1 reference

7 August 2017

H Christian Weber

series ordinal

2

1 reference

7 August 2017

publication date

1 January 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

63

1 reference

7 August 2017

issue

18

1 reference

7 August 2017

page(s)

1895-1905

1 reference

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials

7 August 2017

cites work

1 reference

12 December 2020

Irritable bowel syndrome: a little understood organic bowel disease?

1 reference

12 December 2020

Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome

1 reference

12 December 2020

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome

1 reference

12 December 2020

Systematic review on the management of irritable bowel syndrome in North America.

1 reference

12 December 2020

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

Alosetron for irritable bowel syndrome

1 reference

12 December 2020

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

1 reference

12 December 2020

Irritable bowel syndrome: new agents targeting serotonin receptor subtypes

1 reference

12 December 2020

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

1 reference

12 December 2020

FDA advisory panels recommend Lotronex be put back on market

1 reference

12 December 2020

Ischemic colitis during treatment with alosetron

1 reference

12 December 2020

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome

1 reference

12 December 2020

Review article: clinical pharmacology of alosetron

1 reference

12 December 2020

Alosetron (Lotronex) for treatment of irritable bowel syndrome

1 reference

12 December 2020

Drug treatment options for irritable bowel syndrome: managing for success

1 reference

12 December 2020

Serotoninergic neuroenteric modulators

1 reference

12 December 2020

Alosetron: a case study in regulatory capture, or a victory for patients' rights?

1 reference

12 December 2020

Review article: the complexity of drug development for irritable bowel syndrome

1 reference

12 December 2020

Serotonin: a mediator of the brain-gut connection

1 reference

12 December 2020

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

1 reference

12 December 2020

Alosetron (lotronex) revisited

1 reference

12 December 2020

The irritable bowel syndrome

1 reference

12 December 2020

Evidence-based position statement on the management of irritable bowel syndrome in North America

1 reference

12 December 2020

FDA advisers warn of more deaths if drug is relaunched

1 reference

12 December 2020

FDA allows controversial bowel drug back on to market

1 reference

12 December 2020

Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome

1 reference

12 December 2020

1 reference

12 December 2020

Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron

1 reference

12 December 2020

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

Pharmacology and clinical experience with alosetron

1 reference

12 December 2020

Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity

1 reference

12 December 2020

The treatment of irritable bowel syndrome

1 reference

12 December 2020

Towards positive diagnosis of the irritable bowel

1 reference

12 December 2020

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

1 reference

12 December 2020

Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

1 reference

12 December 2020

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

1 reference

12 December 2020

10.2165/00003495-200363180-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

7 August 2017

1010949210

0 references

1 reference